In vitro heparinization of canine whole blood with low molecular weight heparin (dalteparin) significantly and dose‐dependently prolongs heparinase‐modified tissue factor‐activated thromboelastography parameters and prothrombinase‐induced clotting time
Open Access
- 19 November 2008
- journal article
- Published by Wiley in Veterinary Clinical Pathology
- Vol. 37 (4) , 363-372
Abstract
Background: Low‐molecular‐weight heparin (LMWH) is being used increasingly in veterinary medicine for both treatment and prophylaxis of thromboembolic disease, but no predictable patient‐side method exists to monitor its effect.Objectives: The aim of this study was to evaluate thromboelastography (TEG) and prothombinase‐induced clotting time (PiCT) assays for detecting hemostatic alterations following in vitro heparinization of canine whole blood with dalteparin (Fragmin).Methods: Citrated whole‐blood samples were collected from 7 clinically healthy dogs. Dalteparin was added at concentrations of 0, 0.156, 0.625, 1.25, and 2.5 U/mL of whole blood. TEG was performed using heparinase cups with tissue factor (TF, 1:50,000) and kaolin as activators. Reaction time (R), clotting time (K), angle (α), and maximum amplitude (MA) were recorded. PiCT and anti‐FXa activity were measured in plasma.Results: With TF, increasing concentrations of dalteparin significantly prolonged R and K and significantly decreased α and MA. K, α, and MA ratios were significantly different from baseline at all dalteparin concentrations and R was significantly different from baseline at concentrations of 0.625, 1.25, and 2.5 U/mL. With kaolin, only R was significantly different from baseline at dalteparin concentrations of 0.625 and 2.5 U/mL. PiCT detected dalteparin concentrations ≤ 0.625 U/mL, with a good linear correlation (r2=.96, P<.0001).Conclusion: These results suggest that TF‐activated TEG and PiCT assays should be further evaluated as promising new methods for evaluating the effect of LMWH, using doses in the recommended clinical range and prospective clinical studies.Keywords
This publication has 18 references indexed in Scilit:
- Study on biological variation of haemostatic parameters in clinically healthy dogsThe Veterinary Journal, 2007
- Validation of human recombinant tissue factor–activated thromboelastography on citrated whole blood from clinically healthy dogsVeterinary Clinical Pathology, 2005
- Efficacy of low molecular weight heparin in a canine model of thromboplastin-induced acute disseminated intravascular coagulationResearch in Veterinary Science, 2005
- In vitro comparison of the effect of fondaparinux and enoxaparin on whole blood tissue factor-triggered thromboelastography profileThrombosis and Haemostasis, 2004
- Effect of Phenprocoumon on Monitoring of Lepirudin, Argatroban, Melagatran and Unfractionated Heparin with the PiCT MethodPathophysiology of Haemostasis and Thrombosis, 2002
- The correlation between plasma anti-factor Xa activity and haemostatic tests in healthy dogs, following the administration of a low molecular weight heparinResearch in Veterinary Science, 2000
- Effects of Unfractionated Heparin, Low-Molecular-Weight Heparin, and Heparinoid on Thromboelastographic Assay of Blood CoagulationAmerican Journal of Clinical Pathology, 2000
- Occurrence of thrombosis and haemorrhage, relationship with anti‐Xa, anti‐IIa activities, and D‐dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgeryBritish Journal of Haematology, 1999
- A multicentre comparison of once‐daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosisJournal of Internal Medicine, 1996
- Usefulness of Thrombelastography for Dosage Monitoring of Low Molecular Weight Heparin and Unfractionated Heparin During HemodialysisArtificial Organs, 1990